Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080190 |
| Name | malignant epithelioid hemangioendothelioma |
| Definition | A malignant hemangioma characterized by the presence of epithelioid endothelial cells. The neoplastic cells are arranged in cords and nests, which are embedded in a myxoid to hyalinized stroma. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer cell type cancer malignant hemangioma malignant epithelioid hemangioendothelioma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| IDH2 V305M | Olaparib | malignant epithelioid hemangioendothelioma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02275286 | Phase Ib/II | Trabectedin | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) | Recruiting | ITA | FRA | ESP | 0 |
| NCT03277924 | Phase Ib/II | Nivolumab + Sunitinib | Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) | Completed | ITA | GBR | ESP | 0 |
| NCT04028063 | Phase II | Botensilimab + Doxorubicin Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Recruiting | USA | 0 |
| NCT04741438 | Phase III | Ipilimumab + Nivolumab Pazopanib | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) | Unknown status | FRA | 0 |
| NCT04784247 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
| NCT04857372 | Phase I | IAG933 | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 1 |
| NCT05228015 | Phase I | IK-930 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | Terminated | USA | GBR | AUS | 0 |
| NCT06452160 | Phase I | BGC515 | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06725758 | Phase Ib/II | ODM-212 | Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours (TEADES) | Recruiting | GBR | 0 |
| NCT07014137 | Phase II | ABSK043 | A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas | Recruiting | CAN | 0 |
| NCT07104331 | Phase II | Nab-rapamycin | SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma | Not yet recruiting | USA | 0 |